Pharmacologic control of CAR-T cell function using dasatinib

Blood Adv. 2019 Mar 12;3(5):711-717. doi: 10.1182/bloodadvances.2018028720.

Abstract

  1. Dasatinib potently and reversibly suppresses CAR-T cell cytotoxicity, cytokine secretion, and proliferation.

  2. Dasatinib could be repurposed as a safety switch to mitigate CAR-mediated toxicity in patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD19 / immunology
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cytokines / drug effects
  • Dasatinib / pharmacology*
  • Heterografts
  • Humans
  • Lymphocyte Activation / drug effects
  • Mice
  • Protein Kinase Inhibitors / pharmacology
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology

Substances

  • Antigens, CD19
  • CD19 molecule, human
  • Cytokines
  • Protein Kinase Inhibitors
  • Receptors, Chimeric Antigen
  • Dasatinib